Work

Association of serum interleukin-6 with asthma control and subsequent exacerbations: a retrospective cohort study assessing incremental predictive value

Year: 2026
Type: preprint
Study design: Observational Study
Abstract: Background Circulating interleukin-6 (IL-6) has been associated with adverse asthma outcomes, but its incremental value beyond routine clinical assessment remains uncertain. We evaluated the associations of serum IL-6 with asthma control and 12-month exacerbations and assessed its incremental value beyond the Asthma Control Test (ACT) and clinical variables. Methods This single-centre retrospective cohort included 984 adults with asthma. IL-6 was analysed as a continuous exposure using Pearson correlation, non-parametric receiver operating characteristic analysis and prespecified hierarchical multivariable logistic regression. Models were sequentially adjusted for basic clinical factors, ACT, forced expiratory volume in 1 s (FEV₁) % predicted and fractional exhaled nitric oxide (FeNO). Sensitivity analyses additionally included blood eosinophils and baseline leukotriene receptor antagonist use. Internal optimism in model discrimination was estimated using 1,000 bootstrap resamples. Results Overall, 347 participants (35.3%) experienced an exacerbation within 12 months. IL-6 correlated negatively with ACT (r = − 0.742), FEV₁ % predicted (r = − 0.588) and FEV₁/forced vital capacity (r = − 0.376), and positively with exacerbation (r = 0.413; all P < 0.001). The area under the curve (AUC) for IL-6 alone was 0.752 (95% confidence interval [CI], 0.721–0.783). Each 1-standard-deviation increase in IL-6 was associated with higher odds of exacerbation after basic adjustment (odds ratio [OR], 2.337; 95% CI, 1.982–2.771; P < 0.001). The association was attenuated after adding ACT (OR, 1.247; 95% CI, 1.001–1.553; P = 0.049) and was not statistically significant after further adjustment for FEV₁ % predicted and FeNO (OR, 1.233; 95% CI, 0.988–1.539; P = 0.063). Adding IL-6 to the ACT-based clinical model increased the AUC from 0.817 to 0.819 (DeLong P = 0.333); the bootstrap-corrected AUC was 0.812. The exploratory IL-6 cut-off was 6.015 pg/mL (sensitivity, 81.0%; specificity, 59.7%). Conclusions Serum IL-6 was associated with poorer asthma control and higher odds of exacerbation, but showed no clear incremental discrimination beyond ACT and clinical variables. Its role as a clinical predictor requires external validation.
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W7236145357
Cites: 29
Cited by:
Related to: 10